Copyright
©The Author(s) 2025.
World J Clin Oncol. Feb 24, 2025; 16(2): 98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Table 1 Patient characteristics, n
Characteristics | Combination group | Chemotherapy group |
Age (years) | ||
Median | 54 | 56 |
Range | 45-70 | 48-68 |
Gender | ||
Male | 18 | 15 |
Female | 14 | 19 |
Performance status | ||
0 | 26 | 27 |
1 | 6 | 7 |
Number of liver metastases | ||
1-3 | 22 | 25 |
> 3 | 10 | 09 |
- Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. World J Clin Oncol 2025; 16(2): 98079
- URL: https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i2.98079